Page last updated: 2024-10-24

cefixime and Gonorrhea

cefixime has been researched along with Gonorrhea in 159 studies

Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.

Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.

Research Excerpts

ExcerptRelevanceReference
"To treat Neisseria gonorrhoeae infection, the Centers for Disease Control and Prevention recommends a single oral dose of cefixime as an alternative to injectable ceftriaxone."9.41Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis. ( Bristow, CC; Klausner, JD; Kojima, N; Yang, KJ, 2023)
"Comparator studies reporting adverse effect outcomes of treatment with cefixime, ceftriaxone, or gentamicin for gonorrhea in humans were included."9.12Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021)
"Both intramuscular ceftriaxone 125 mg and oral cefixime 400 mg appear to be effective for the treatment of gonococcal infection in pregnancy."9.09A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. ( Mayfield, JA; Ramus, RM; Sheffield, JS; Wendel, GD, 2001)
" During 1996-1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure."9.09A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. ( Aplasca De Los Reyes, MR; Dallabetta, G; Holmes, KK; Klausner, JD; Manalastas, R; Pato-Mesola, V; Tuazon, CU; Whittington, WL; Wi, T, 2001)
"In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg)."9.08Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. ( Bean, K; Hook, EW; Jones, RB; Maroli, AN; Martin, D; McCormack, WM, 1997)
"In a randomized, unblinded multicenter study of 209 men and 124 women with uncomplicated gonorrhea, we compared three single-dose treatment regimens: 400 mg or 800 mg of cefixime, administered orally, and 250 mg of ceftriaxone administered intramuscularly."9.07A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. ( Covino, JM; Douglas, JM; Ehret, JM; Handsfield, HH; Hook, EW; McCormack, WM; Reichart, CA; Verdon, MS, 1991)
"In this randomized study, a single 800-mg oral dose of cefixime cured 96 of 97 men with uncomplicated gonococcal urethritis, compared with 44 cures of 46 men who received standard therapy with amoxicillin (3 g) plus probenecid (1 g)."9.06Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. ( Bowie, WR; Lefebvre, K; Megran, DW; Willetts, V, 1990)
"Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993."8.12Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022)
"Both regimens were highly effective in treating gonorrhea with success rates of 96."7.11Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection. ( Nguyen, HT; Nguyen, HV; Nguyen, PTT; Pham, HV; Pham, LV; Van, DH, 2022)
"To treat Neisseria gonorrhoeae infection, the Centers for Disease Control and Prevention recommends a single oral dose of cefixime as an alternative to injectable ceftriaxone."5.41Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis. ( Bristow, CC; Klausner, JD; Kojima, N; Yang, KJ, 2023)
" Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval."5.32Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. ( Deguchi, T; Harada, Y; Ishida, K; Ishihara, S; Ito, M; Kojima, K; Maeda, S; Minamidate, K; Tamaki, M; Tei, K; Yasuda, M; Yokoi, S, 2003)
"Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains."5.28[Cefixime therapy in patients with proven gonorrhea]. ( Backhaus, A; Tinzl, J, 1990)
"Comparator studies reporting adverse effect outcomes of treatment with cefixime, ceftriaxone, or gentamicin for gonorrhea in humans were included."5.12Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis. ( Dresser, J; Wilby, KJ, 2021)
"Both intramuscular ceftriaxone 125 mg and oral cefixime 400 mg appear to be effective for the treatment of gonococcal infection in pregnancy."5.09A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. ( Mayfield, JA; Ramus, RM; Sheffield, JS; Wendel, GD, 2001)
" During 1996-1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure."5.09A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. ( Aplasca De Los Reyes, MR; Dallabetta, G; Holmes, KK; Klausner, JD; Manalastas, R; Pato-Mesola, V; Tuazon, CU; Whittington, WL; Wi, T, 2001)
"In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg)."5.08Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. ( Bean, K; Hook, EW; Jones, RB; Maroli, AN; Martin, D; McCormack, WM, 1997)
"In a randomized, unblinded multicenter study of 209 men and 124 women with uncomplicated gonorrhea, we compared three single-dose treatment regimens: 400 mg or 800 mg of cefixime, administered orally, and 250 mg of ceftriaxone administered intramuscularly."5.07A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. ( Covino, JM; Douglas, JM; Ehret, JM; Handsfield, HH; Hook, EW; McCormack, WM; Reichart, CA; Verdon, MS, 1991)
"In this randomized study, a single 800-mg oral dose of cefixime cured 96 of 97 men with uncomplicated gonococcal urethritis, compared with 44 cures of 46 men who received standard therapy with amoxicillin (3 g) plus probenecid (1 g)."5.06Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. ( Bowie, WR; Lefebvre, K; Megran, DW; Willetts, V, 1990)
"Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993."4.12Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. ( Bonongwe, N; Chen, JS; Chikaonda, T; Cohen, MS; Golparian, D; Hobbs, MM; Hoffman, IF; Jere, E; Kamtambe, B; Krysiak, R; Massa, C; Mathiya, E; Matoga, M; Ndalama, B; Unemo, M, 2022)
"Oral cefixime or ceftriaxone injections were used as first-line drugs for the treatment of gonorrhea from 2006 to 2013 because gonorrhea isolates had low minimum inhibitory concentrations for these two drugs."3.83Changes in the six most common sequence types of Neisseria gonorrhoeae, including ST4378, identified by surveillance of antimicrobial resistance in northern Taiwan from 2006 to 2013. ( Cheng, CW; Li, LH; Li, SY; Su, CY; Yen, MY, 2016)
"Although cephalosporins are the cornerstone of treatment of Neisseria gonorrhoeae infections, cefixime is the only oral antimicrobial option."3.79Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. ( Allen, VG; Lee, C; Low, DE; Martin, IE; Melano, RG; Mitterni, L; Rebbapragada, A; Seah, C; Siebert, H; Towns, L, 2013)
"Recently, the first Neisseria gonorrhoeae strain (H041) highly resistant to the expanded-spectrum cephalosporins (ESCs) ceftriaxone and cefixime, which are the last remaining options for first-line gonorrhea treatment, was isolated in Japan."3.78High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. ( Gallay, A; Golparian, D; Nicholas, R; Ohnishi, M; Sednaoui, P; Unemo, M, 2012)
"Ciprofloxacin resistant gonorrhea (CRG) cultures rose from 1."3.75Antimicrobial resistance in gonorrhea: the influence of epidemiologic and laboratory surveillance data on treatment guidelines: Alberta, Canada 2001-2007. ( Boyington, C; Lovgren, M; Plitt, S; Read, R; Singh, AE; Sutherland, K; Tilley, P, 2009)
"Both regimens were highly effective in treating gonorrhea with success rates of 96."3.11Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection. ( Nguyen, HT; Nguyen, HV; Nguyen, PTT; Pham, HV; Pham, LV; Van, DH, 2022)
" Drug concentrations over time will be used to develop mathematical models for optimisation of drug dosing regimens and to estimate pharmacodynamic targets of efficacy."3.11Optimisation of treatments for oral ( Chow, EPF; Fairley, CK; Hammoud, MA; Hocking, JS; Kong, FYS; Landersdorfer, CB; Latch, N; Lewis, DA; Lim, SH; Parker, SL; Roberts, JA; Unemo, M; Wallis, SC; Williamson, DA; Yap, T, 2022)
"We conducted an open-label, nonrandomized, phase I pharmacokinetic and safety study of cefixime in 25 healthy male and female volunteers divided into 4 dosing cohorts (cohort A, 400 mg; cohort B, 800 mg; cohort C, 1200 mg; and cohort D, 800 mg every 8 hours × 3 doses [total dose 2400 mg]) with a target serum concentration of at least 2."2.87A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx. ( Barbee, LA; Blumer, JL; Golden, MR; Gray, W; Griffiss, JM; Nayak, SU; OʼRiordan, MA; Zenilman, JM, 2018)
"10) or adverse effects (OR 1."2.48Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. ( Bai, ZG; Bao, XJ; Cheng, WD; Li, YP; Yang, KH, 2012)
" Acquisition of plasmids from other bacteria and long-term use of a single agent has selected both single step high-level and low-level resistance due to multiple mutations."2.47Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. ( Alexander, S; Ison, CA, 2011)
"Oral regimens for the treatment of gonorrhea are limited."2.46Emergence and spread of drug resistant Neisseria gonorrhoeae. ( Deguchi, T; Maeda, S; Nakane, K; Yasuda, M, 2010)
"We present a case of gonococcal septic arthritis of the right hip diagnosed via synovial fluid cultures."1.72Right hip gonococcal septic arthritis treatment with successful transition to oral fluoroquinolone. ( Kiamos, A; Sands, M; Torrente, N; Verdecia, J, 2022)
"Cefixime resistance was detected in 2."1.48Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. ( Amato-Gauci, AJ; Cole, MJ; Day, MJ; Jacobsson, S; Spiteri, G; Unemo, M; Woodford, N, 2018)
"Ciprofloxacin resistance was seen in < 5% of isolates prior to 2010, but in > 5% thereafter."1.48High levels of susceptibility to new and older antibiotics in Neisseria gonorrhoeae isolates from Saskatchewan (2003-15): time to consider point-of-care or molecular testing for precision treatment? ( Dillon, JR; Horsman, GB; Levett, PN; Thakur, SD, 2018)
"Cefixime was recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which time resistance increased, and subsequently declined."1.46Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study. ( Didelot, X; White, PJ; Whittles, LK, 2017)
"The EC 50 of the dose-response curves correlated well with Etest MIC values (Pearson's r  = 0."1.46A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. ( Althaus, CL; Desilvestro, V; Foerster, S; Hathaway, LJ; Unemo, M, 2017)
"Cefixime resistance was detected in 13 (61."1.42Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. ( Cole, MJ; Grigorjev, V; Jacobsson, S; Pitt, R; Spiteri, G; Unemo, M, 2015)
"gonorrhea control efforts, but treatment of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance."1.38Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. ( , 2012)
"Gonorrhea is a worldwide sexually transmitted disease (STD) caused by Neisseria gonorrhoeae."1.33Gonorrhea: update. ( Little, JW, 2006)
" Subsequently, a dosing interval of 6 h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval."1.32Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. ( Deguchi, T; Harada, Y; Ishida, K; Ishihara, S; Ito, M; Kojima, K; Maeda, S; Minamidate, K; Tamaki, M; Tei, K; Yasuda, M; Yokoi, S, 2003)
"Cefixime was kept for patients not responding to the first GU treatment."1.31Cost-effectiveness of management strategies for acute urethritis in the developing world. ( Crabbé, F; de Clerck, M; Laga, M; Vuylsteke, B, 2000)
"Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains."1.28[Cefixime therapy in patients with proven gonorrhea]. ( Backhaus, A; Tinzl, J, 1990)

Research

Studies (159)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.63)18.7374
1990's13 (8.18)18.2507
2000's21 (13.21)29.6817
2010's85 (53.46)24.3611
2020's39 (24.53)2.80

Authors

AuthorsStudies
Kueakulpattana, N1
Wannigama, DL1
Luk-In, S1
Hongsing, P1
Hurst, C1
Badavath, VN1
Jenjaroenpun, P2
Wongsurawat, T2
Teeratakulpisan, N1
Kerr, SJ1
Abe, S1
Phattharapornjaroen, P1
Shein, AMS1
Saethang, T1
Chantaravisoot, N1
Amarasiri, M1
Higgins, PG1
Chatsuwan, T1
Matoga, M1
Chen, JS1
Krysiak, R1
Ndalama, B1
Massa, C1
Bonongwe, N1
Mathiya, E1
Kamtambe, B1
Jere, E1
Chikaonda, T1
Golparian, D7
Unemo, M30
Cohen, MS1
Hobbs, MM1
Hoffman, IF2
Allen, H2
Merrick, R1
Ivanov, Z1
Pitt, R2
Mohammed, H1
Sinka, K1
Hughes, G4
Fifer, H1
Cole, MJ16
Lin, X2
Qin, X2
Wu, X2
Liao, Y2
Yu, Y1
Xie, Q2
Tang, S1
Guo, C1
Pei, J1
Wu, Z1
Cai, C1
Wang, F1
Wu, S1
Chen, H1
Liu, X2
Li, M1
Cao, W2
Zheng, H2
Lahra, MM2
Escher, M1
Eremin, S1
Galarza, P3
Ndowa, F2
Martin, I5
Dillon, JR3
Galas, M1
Ramon-Pardo, P1
Weinstock, H4
Wi, T3
Sánchez-Busó, L1
Spiteri, G9
Day, M3
Jacobsson, S8
Sajedi, N2
Yeats, CA1
Abudahab, K1
Underwood, A1
Bluemel, B1
Aanensen, DM1
Day, MJ2
Kulishev, C1
Woodford, N4
Blumel, B1
van der Werf, MJ1
Amato-Gauci, AJ5
Nguyen, PTT1
Pham, HV1
Van, DH1
Pham, LV1
Nguyen, HT1
Nguyen, HV1
Allan-Blitz, LT2
Adamson, PC1
Klausner, JD6
Jorge-Berrocal, A1
Vargas-Herrera, N1
Benites, C1
Salazar-Quispe, F1
Mayta-Barrios, M1
Barrios-Cárdenas, YJ1
Melano, RG4
Yagui, M1
Nokchan, N1
Nitayanon, P1
Tribuddharat, C1
Schörner, MA1
Mesa, D1
Barazzetti, FH1
Martins, JM1
Machado, HM1
Grisard, HBDS1
Wachter, JK1
Starick, MR1
Scheffer, MC1
Palmeiro, JK1
Bazzo, ML1
Shimuta, K4
Takahashi, H1
Akeda, Y1
Nakayama, SI1
Ohnishi, M6
Kiamos, A1
Torrente, N1
Sands, M1
Verdecia, J1
Tang, EC1
Johnson, KA1
Alvarado, L1
Burghardt, NO1
Hernandez, C1
Lopez, E1
Jenkins-Barnes, T1
Hughes, B1
Salas, KL1
Jacobson, KR1
Kong, FYS1
Lim, SH1
Latch, N1
Williamson, DA1
Roberts, JA1
Wallis, SC1
Parker, SL1
Landersdorfer, CB1
Yap, T1
Fairley, CK1
Chow, EPF1
Lewis, DA2
Hammoud, MA1
Hocking, JS1
Yang, KJ1
Kojima, N1
Bristow, CC1
Xiu, L1
Wang, L1
Li, Y1
Hu, L1
Huang, J1
Yong, G1
Wang, Y1
Dong, Y1
Gu, W1
Peng, J1
Lin, HH1
Li, JW1
Yang, TY1
Lee, CY1
Jain, SH1
Lin, SY1
Lu, PL1
Riou, J1
Althaus, CL3
Grad, YH4
Heijne, JCM1
Low, N1
Li, X1
Yin, X1
Liu, M1
Pan, Y1
Zeng, L1
Yang, J1
Feng, Z1
Tang, Y1
Chen, W1
Luo, X1
Zhuang, P1
Li, R1
Blouin, K1
Lefebvre, B2
Trudelle, A1
Defay, F1
Perrault Sullivan, G1
Ezin Aloffan, LND1
Labbé, AC1
Yasuda, M7
Takahashi, S2
Miyazaki, J1
Wada, K1
Kobayashi, K1
Matsumoto, M1
Hayami, H1
Yamamoto, S1
Kiyota, H1
Sato, J1
Matsumoto, T1
Yotsuyanagi, H1
Hanaki, H1
Masumori, N1
Hiyama, Y2
Nishiyama, H1
Kimura, T1
Yamada, H1
Matsumoto, K1
Ishikawa, K1
Togo, Y1
Tanaka, K1
Sadahira, T1
Inokuchi, J1
Hamasuna, R1
Ito, K1
Hirayama, H1
Hayashi, K1
Kurimura, Y2
Kadena, H1
Ito, S5
Shiono, Y1
Maruyama, T1
Ito, M3
Hatano, K1
Chokyu, H1
Ihara, H1
Uno, S1
Monden, K1
Yokoyama, T1
Kano, M1
Kaji, S1
Kawahara, M1
Sumii, T1
Tojo, T1
Hosobe, T1
Naito, K1
Kawai, S1
Nishimura, H1
Izumitani, M1
Yoh, M1
Matsumura, M1
Fujita, R1
Takayama, K1
Hara, M1
Nishi, S1
Ma, A1
Ferrato, C1
Smyczek, P1
Gratrix, J3
Dingle, TC1
Deng, X2
Młynarczyk-Bonikowska, B1
Majewska, A1
Malejczyk, M1
Młynarczyk, G1
Majewski, S1
Quinten, C1
Indriatmi, W1
Prayogo, RL1
Nilasari, H1
Suseno, LS1
Palavecino, EL1
Kilic, A1
Schmerer, MW1
Dobre-Buonya, O1
Toler, C1
McNeil, CJ1
Workneh, M1
Hamill, MM1
Kakooza, F1
Mande, E1
Wagner, J1
Mbabazi, O1
Mugasha, R1
Kajumbula, H1
Walwema, R1
Zenilman, J1
Musinguzi, P1
Kyambadde, P1
Lamorde, M1
Manabe, YC1
Pinto, M1
Matias, R1
Rodrigues, JC1
Duarte, S1
Vieira, L1
Gonçalves, I1
Gonçalves, MJ1
Ramos, MH1
Gomes, JP1
Borrego, MJ1
Selb, R1
Jansen, K3
Eckardt, M1
Tamminga, T2
Dudareva, S3
Gassowski, M1
Graeber, I2
Guhl, E3
Heuer, D2
Buder, S3
Dresser, J1
Wilby, KJ1
Banhart, S1
Calvignac-Spencer, S1
Pilz, T1
Martini, A1
Nikisins, S2
Dehmel, K1
Zuelsdorf, G1
Kohl, PK4
Bremer, V2
Miller, S1
Degener, T1
Patel, P1
Picker, MA1
Knoblock, RJ1
Hansen, H1
Bautista, I1
Griego, R1
Barber, L1
Bendik, W1
Lam, K1
Adelman, E1
Qiu-Shultz, Z1
Raphael, BH1
Pham, CD1
Kersh, EN1
St Cyr, SB1
Oree, G1
Naicker, M1
Maise, HC1
Tinarwo, P1
Ramsuran, V1
Abbai, NS1
Eyre, DW2
De Silva, D2
Cole, K2
Peters, J2
Demczuk, W1
Mulvey, MR1
Crook, DW2
Walker, AS2
Peto, TEA1
Paul, J2
Foerster, S1
Desilvestro, V1
Hathaway, LJ1
Latif, AS1
Gwanzura, L1
Machiha, A1
Tarupiwa, A1
Gudza-Mugabe, M1
Shukusho, FD1
Chakanyuka Musanhu, C1
Gianecini, R2
Romero, MLM1
Oviedo, C2
Vacchino, M1
Tripodo, F1
Thakur, SD3
Levett, PN3
Horsman, GB3
Whittles, LK1
White, PJ1
Didelot, X2
Papp, JR1
Rowlinson, MC1
O'Connor, NP1
Wholehan, J1
Razeq, JH1
Glennen, A1
Ware, D1
Iwen, PC1
Lee, LV1
Hagan, C1
Loenenbach, A1
Sailer, A1
Comunián-Carrasco, G1
Peña-Martí, GE1
Martí-Carvajal, AJ1
Barbee, LA2
Nayak, SU1
Blumer, JL1
OʼRiordan, MA1
Gray, W1
Zenilman, JM1
Golden, MR2
Griffiss, JM1
Tanaka, M1
Furuya, R1
Kobayashi, I1
Kanesaka, I1
Ohno, A1
Katsuse, AK1
Singh, A1
Tomberg, J1
Nicholas, RA1
Davies, C1
Sriruttan, C1
Müller, EE1
Gumede, L1
Fick, D1
de Wet, J1
Maseko, V1
Coetzee, J1
Kerndt, P1
Allen, VG3
Low, DE3
Kirkcaldy, RD4
Bolan, GA2
Wasserheit, JN2
Wright, DJ1
Azadian, B1
Ison, CA10
Town, K4
Obi, C3
Chisholm, S3
Livermore, DM2
Lowndes, CM4
Nakayama, S3
Morita-Ishihara, T2
Dorin, M1
Kawahata, T2
Singh, AE3
Read, R3
Lovgren, M2
Drews, SJ2
Romanowski, B1
Sutherland, K2
Talbot, J1
Kidd, S2
Lee, MV2
Maningas, E1
Komeya, A1
Kunimoto, G1
O'Connor, N2
Katz, AR1
Wasserman, GM1
Whelen, AC1
Brooks, B1
Cole, M1
Ross, JD1
White, JA1
Patel, R1
Bergman, J1
Egan, C1
McCormick, DF1
Rahman, M1
Zadrozny, S1
Alam, A1
Ashraf, L1
Neilsen, GA1
Kelly, R1
Menezes, P1
Miller, WC1
Kovari, H1
de Melo Oliveira, MD1
Hauser, P1
Läuchli, S1
Meyer, J1
Weber, R1
Zbinden, R1
Trees, D1
Dordel, J1
Harris, SR1
Goldstein, E1
Parkhill, J1
Hanage, WP1
Bentley, S1
Lipsitch, M1
Quaye, N1
Yu, RX2
Yin, Y2
Wang, GQ1
Chen, SC2
Zheng, BJ2
Dai, XQ2
Han, Y2
Li, Q1
Zhang, GY2
Chen, X1
Dillon, JA2
Starnino, S1
Endimiani, A1
Guilarte, YN1
Tinguely, R1
Hirzberger, L1
Selvini, S1
Lupo, A1
Hauser, C1
Furrer, H1
La Ruche, G1
Sednaoui, P2
Berçot, B1
Cambau, E1
Semaille, C1
Deguchi, T6
Tsuchiya, T1
Yokoi, S4
Donovan, B1
Whiley, DM2
Furubayashi, K1
Chisholm, SA3
Hoffmann, S2
Van de Laar, M2
Cheng, CW1
Li, LH1
Su, CY1
Li, SY1
Yen, MY1
Grigorjev, V1
Peters, RP1
Verweij, SP1
McIntyre, JA1
Schaftenaar, E1
Stafforini, G1
Carannante, A1
Vacca, P1
Ghisetti, V1
Latino, MA1
Cusini, M1
Matteelli, A1
Vocale, C1
Prignano, G1
Leli, C1
Ober, P1
Antonetti, R1
Poletti, F1
Stefanelli, P1
Cresswell, F1
Dean, G1
Dave, J1
Thomas, DR1
Foster, K1
Waldram, A1
Wilson, DJ1
Peto, TE1
Brunner, A1
Nemes-Nikodem, E1
Jeney, C1
Szabo, D1
Marschalko, M1
Karpati, S1
Ostorhazi, E1
Costa-Lourenço, APR1
Abrams, JA1
Barros Dos Santos, KT1
Coelho-Souza, T1
Moreira, BM1
Fracalanzza, SEL1
Trees, DL2
Bonelli, RR1
Chen, XS1
Tapsall, JW2
Plitt, S1
Boyington, C1
Tilley, P1
Watanabe, Y1
Ono, E1
Takahashi, C1
Oya, H1
Kuroki, T1
Okazaki, N1
Watanabe, H1
Brill, JR1
Nakane, K1
Maeda, S3
Hellmark, B1
Fredlund, H1
Nissen, MD1
Sloots, TP1
Klingler, A1
Farrell, DJ1
Rebbapragada, A2
Tan, J1
Tijet, N1
Perusini, SJ1
Towns, L2
Lo, S1
Syversen, G1
Vestrheim, DF2
Moi, H2
Hussey, J1
Sankar, KN1
Evans, J1
Alexander, S3
Hartgill, U1
Jakopanec, I1
Limnios, A1
Tapsall, J1
Kahlmeter, J1
Hogan, T1
Ray, S1
Lam, A1
Forsyth, S1
Penney, P1
Rooney, G1
Desouza-Thomas, L1
Maclure-Webster, E1
Anderson, J1
Nichols, T1
Bala, M1
Stary, A1
Eigentler, A1
Nicholas, R1
Gallay, A1
Hjelmevoll, SO1
Olsen, ME1
Sollid, JU1
Haaheim, H1
Melby, KK1
Skogen, V1
Sawatzky, P1
Allen, V1
Hoang, L1
Mina, N1
Wong, T1
Gilmour, M1
Bai, ZG1
Bao, XJ1
Cheng, WD1
Yang, KH1
Li, YP1
Hashimoto, J1
Uehara, T1
Iwasawa, A1
Nishimura, M1
Sunaoshi, K1
Takeda, K1
Suzuki, N1
Tsukamoto, T1
Kirkcaldy, R1
Bolan, G1
Pereira, R1
Maldonado, NG1
Takhar, SS1
Mitterni, L1
Seah, C1
Martin, IE1
Lee, C1
Siebert, H1
Ishida, K1
Ishihara, S2
Minamidate, K1
Harada, Y1
Tei, K1
Kojima, K1
Tamaki, M2
Wang, SA1
Iverson, CJ1
Ohye, RG1
Whiticar, PM1
Hale, JA1
Knapp, JS1
Effler, PV1
Weinstock, HS1
Levenson, D1
Mizutani, KS1
Takahashi, Y1
Kawamura, Y1
Ezaki, T1
Whittington, WL2
Handsfield, HH2
Hughes, JP1
Stamm, WE1
Hogben, M1
Clark, A1
Malinski, C1
Helmers, JR1
Thomas, KK1
Holmes, KK2
Barlam, TF1
Little, JW1
Asbel, LE1
Newbern, EC1
Salmon, M1
Spain, CV1
Goldberg, M1
Takahata, S1
Senju, N1
Osaki, Y1
Yoshida, T1
Ida, T1
McMillan, A1
Young, H1
Sathia, L1
Ellis, B1
Phillip, S1
Winston, A1
Smith, A1
Ozawa, T1
Kubota, Y1
Dalla Vestra, M1
Rettore, C1
Sartore, P1
Velo, E1
Sasset, L1
Chiesa, G1
Marcon, L1
Scarano, L1
Simioni, N1
Bacelle, L1
Patrassi, GM1
Klepser, ME1
Quintiliani, R1
Nightingale, CH1
Loughlin, KA1
Bakst, CM1
Rybak, MJ1
Friedland, LR1
Kulick, RM1
Biro, FM1
Patterson, A1
Tu, Y1
Kratofiel, M1
Petzoldt, D1
Hook, EW2
McCormack, WM2
Martin, D1
Jones, RB1
Bean, K1
Maroli, AN1
Crabbé, F1
Vuylsteke, B1
de Clerck, M1
Laga, M1
Aplasca De Los Reyes, MR1
Pato-Mesola, V1
Manalastas, R1
Tuazon, CU1
Dallabetta, G1
Ramus, RM1
Sheffield, JS1
Mayfield, JA1
Wendel, GD1
Plourde, PJ1
Tyndall, M1
Agoki, E1
Ombette, J1
Slaney, LA1
D'Costa, LJ1
Ndinya-Achola, JO1
Plummer, FA1
Holdcroft, C1
Asbach, HW1
Di Nola, F1
Arione, R1
Bramato, C1
Douglas, JM1
Covino, JM1
Verdon, MS1
Reichart, CA1
Ehret, JM1
Cates, W1
Hinman, AR1
Backhaus, A1
Tinzl, J1
Megran, DW1
Lefebvre, K1
Willetts, V1
Bowie, WR1
Kuhlwein, A1
Nies, BA1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Efficacy of Two Combination Regimens for the Treatment of Uncomplicated Neisseria Gonorrhoeae and Chlamydia Trachomatis Coinfection[NCT05216744]Phase 2125 participants (Actual)Interventional2021-07-15Completed
The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study[NCT01949363]Phase 125 participants (Actual)Interventional2013-12-31Completed
Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women[NCT03752112]Phase 1/Phase 2180 participants (Anticipated)Interventional2019-11-22Recruiting
Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis in Extragenital Sites[NCT02870101]2,767 participants (Actual)Interventional2017-04-10Completed
Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk[NCT01510262]130 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

14 reviews available for cefixime and Gonorrhea

ArticleYear
Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis.
    Sexually transmitted diseases, 2023, 03-01, Volume: 50, Issue:3

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisse

2023
Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.
    Medical microbiology and immunology, 2020, Volume: 209, Issue:2

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple

2020
Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:7

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gentamicins; Gonorrhea; Humans; Injections, Intramuscu

2021
Antibiotics for treating gonorrhoea in pregnancy.
    The Cochrane database of systematic reviews, 2018, 02-21, Volume: 2

    Topics: Amoxicillin; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Female; Gonorrhea; Humans; Pregnancy; Pre

2018
Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Female; Gonorrhea; Humans; Male; Neisseri

2014
Preparing for an era of untreatable gonorrhea.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:3

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cephalosporins

2014
Emergence and spread of drug resistant Neisseria gonorrhoeae.
    The Journal of urology, 2010, Volume: 184, Issue:3

    Topics: Azithromycin; Cefixime; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Neisseria g

2010
Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management.
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:10

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Disease Management; Drug Resistance, Multiple, Bacteri

2011
Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.
    International journal of STD & AIDS, 2012, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Middle Aged; Odd

2012
[Gonorrhea].
    Der Urologe. Ausg. A, 2006, Volume: 45, Issue:12

    Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; Practice Guidelines as Topic; Practice Patterns,

2006
Treatment of uncomplicated infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae.
    Connecticut medicine, 1994, Volume: 58, Issue:8

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Cefotaxime; Chlamydia Infections; Chlamydia trachomat

1994
Oral treatment of gonorrhea and chlamydia.
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Cefixime; Cefotaxime; Chlamydia Infections; Ciprofloxac

1994
Gonorrhoea: single-dose oral treatment.
    Current problems in dermatology, 1996, Volume: 24

    Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Cefotaxi

1996
[Cefixime. Microbiologic, kinetic and clinical profile].
    Minerva medica, 1991, Volume: 82, Issue:10

    Topics: Animals; Bacteria; Cefixime; Cefotaxime; Gonorrhea; Humans; Microbial Sensitivity Tests; Otitis Medi

1991

Trials

13 trials available for cefixime and Gonorrhea

ArticleYear
Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection.
    BMC infectious diseases, 2022, Jul-09, Volume: 22, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Chlamydia Infections; Chlamydia trachomatis; Coinfecti

2022
Optimisation of treatments for oral
    BMJ open, 2022, Nov-11, Volume: 12, Issue:11

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Gonorrhea; Humans; Male; Neisseria gonorrhoeae

2022
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
    Sexually transmitted diseases, 2018, Volume: 45, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu

2018
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
    Sexually transmitted diseases, 2018, Volume: 45, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu

2018
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
    Sexually transmitted diseases, 2018, Volume: 45, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu

2018
A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.
    Sexually transmitted diseases, 2018, Volume: 45, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalosporins; Cohort Stu

2018
Prevention and control of sexually transmissible infections among hotel-based female sex workers in Dhaka, Bangladesh.
    Sexual health, 2013, Volume: 10, Issue:6

    Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bangladesh; Candidiasis, Vulvovaginal; Cefixime; Ch

2013
Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.
    The New England journal of medicine, 2005, Feb-17, Volume: 352, Issue:7

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Contact Tracing; Drug Th

2005
Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:8

    Topics: Administration, Oral; Adolescent; Anti-Infective Agents; beta-Lactam Resistance; Cefixime; Cefotaxim

1997
A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, May-01, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Anti-Infective Agents; Cefixime; Cephalosporins; Ciprofloxacin; Drug Resistance,

2001
A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy.
    American journal of obstetrics and gynecology, 2001, Volume: 185, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Anus Diseases; Cefixime; Ceftriaxone; Cephalosporins; Chlam

2001
Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection.
    The Journal of infectious diseases, 1992, Volume: 166, Issue:4

    Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cefixime; Cefotaxime; Ceftriaxone; Drug Ev

1992
Cefixime offers effective oral therapy for gonorrhea.
    The Nurse practitioner, 1992, Volume: 17, Issue:5

    Topics: Anti-Infective Agents, Urinary; Cefixime; Cefotaxime; Ceftriaxone; Female; Gonorrhea; Humans; Male

1992
Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea.
    Drugs, 1991, Volume: 42 Suppl 4

    Topics: Acute Disease; Administration, Oral; Cefixime; Cefotaxime; Cystitis; Double-Blind Method; Female; Go

1991
A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group.
    The New England journal of medicine, 1991, Nov-07, Volume: 325, Issue:19

    Topics: Administration, Oral; Adolescent; Adult; Cefixime; Cefotaxime; Ceftriaxone; Drug Resistance, Microbi

1991
Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.
    Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Amoxicillin; Cefixime; Cefotaxime; Gonorrhea; Humans; Male; Probenecid; Randomize

1990

Other Studies

132 other studies available for cefixime and Gonorrhea

ArticleYear
Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand.
    Scientific reports, 2021, 11-04, Volume: 11, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Drug

2021
Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi.
    Sexually transmitted diseases, 2022, 04-01, Volume: 49, Issue:4

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Female; Gentamicins; Gono

2022
Is there an association between previous infection with
    Sexually transmitted infections, 2023, Volume: 99, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cross-Sectional Studies; Drug Resistance, Bacterial; E

2023
Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.
    Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cephalosporins

2022
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study.
    The Lancet. Microbe, 2021, Volume: 2, Issue:11

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria

2021
Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study.
    The Lancet. Microbe, 2022, Volume: 3, Issue:6

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Europe; Geno

2022
Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019.
    BMC infectious diseases, 2022, Jun-07, Volume: 22, Issue:1

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Dr

2022
Resistance-Guided Therapy for Neisseria gonorrhoeae.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-29, Volume: 75, Issue:9

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Gonorrhea;

2022
Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates From Peru, 2018 and 2019.
    Sexually transmitted diseases, 2022, 10-01, Volume: 49, Issue:10

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria

2022
Whole-genome sequence analysis of high-level penicillin-resistant strains and antimicrobial susceptibility of Neisseria gonorrhoeae clinical isolates from Thailand.
    PloS one, 2022, Volume: 17, Issue:7

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Go

2022
    Frontiers in cellular and infection microbiology, 2022, Volume: 12

    Topics: Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisseria gonorr

2022
Loop-Mediated Isothermal Amplification Assay for Identifying Neisseria gonorrhoeae Nonmosaic
    Microbiology spectrum, 2022, 10-26, Volume: 10, Issue:5

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gon

2022
Right hip gonococcal septic arthritis treatment with successful transition to oral fluoroquinolone.
    BMJ case reports, 2022, Sep-16, Volume: 15, Issue:9

    Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance,

2022
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020-July 2021.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 01-13, Volume: 76, Issue:2

    Topics: Adult; Anti-Bacterial Agents; California; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrh

2023
Multicentre Clinical Evaluation of a Molecular Diagnostic Assay to Identify Neisseria gonorrhoeae Infection and Detect Antimicrobial Resistance.
    International journal of antimicrobial agents, 2023, Volume: 61, Issue:5

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H

2023
Emergence of a predominant sequence type ST7363 and the increasing trend of resistance to cefixime and ceftriaxone in Neisseria gonorrhoeae in Southern Taiwan, 2019-2021.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2023, Volume: 56, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonor

2023
Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study.
    BMC infectious diseases, 2023, Apr-20, Volume: 23, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria

2023
Dissemination of Neisseria gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins in Southern China, 2021: a genome-wide surveillance from 20 cities.
    Annals of clinical microbiology and antimicrobials, 2023, May-17, Volume: 22, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporins; Cities; Gonorrhea; Humans; Microbial S

2023
Antimicrobial Resistance Profiling and Genome Analysis of the penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021.
    The Journal of infectious diseases, 2023, 09-15, Volume: 228, Issue:6

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H

2023
Correlates of
    BMJ open, 2023, 08-04, Volume: 13, Issue:8

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Cross-Sectional St

2023
The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016-2017.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:11

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Gonorrhea; Humans

2023
Use of genome sequencing to resolve differences in gradient diffusion and agar dilution antimicrobial susceptibility testing performance of
    Journal of clinical microbiology, 2023, Nov-21, Volume: 61, Issue:11

    Topics: Agar; Alberta; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Gonorrhea;

2023
Six penA Codons Accurately and Reliably Predict Cefixime-Decreased Susceptibility in Neisseria gonorrhoeae.
    The Journal of infectious diseases, 2020, 02-18, Volume: 221, Issue:5

    Topics: Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Codon; Evolution, Molecular; Gonorrhea; Humans;

2020
The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area.
    BMC infectious diseases, 2019, Dec-10, Volume: 19, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; European U

2019
Antimicrobial resistance of Neisseria gonorrhoeae in Jakarta, Indonesia: a cross-sectional study.
    Sexual health, 2020, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cross-Sectional Studie

2020
First Case of High-Level Azithromycin-Resistant Neisseria gonorrhoeae in North Carolina.
    Sexually transmitted diseases, 2020, Volume: 47, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonor

2020
Antimicrobial Resistance of Neisseria Gonorrhoeae in a Newly Implemented Surveillance Program in Uganda: Surveillance Report.
    JMIR public health and surveillance, 2020, 06-10, Volume: 6, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Ciprofloxacin; Demography; Drug Resistance, Bac

2020
Cephalosporin-Resistant Neisseria gonorrhoeae Isolated in Portugal, 2019.
    Sexually transmitted diseases, 2020, Volume: 47, Issue:11

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea

2020
External quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in primary laboratories in Germany.
    BMC infectious diseases, 2020, Jul-16, Volume: 20, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria

2020
Molecular epidemiological typing of
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020, Volume: 25, Issue:41

    Topics: Adult; Cefixime; Drug Resistance, Multiple, Bacterial; Female; Germany; Gonorrhea; Humans; Male; Mic

2020
Pain in the eye: a case of gonococcal orbital cellulitis.
    Sexually transmitted infections, 2021, Volume: 97, Issue:4

    Topics: Adult; Cefixime; Ciprofloxacin; Female; Gonorrhea; Humans; Neisseria gonorrhoeae; Orbital Cellulitis

2021
Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone.
    MMWR. Morbidity and mortality weekly report, 2020, 12-11, Volume: 69, Issue:49

    Topics: Alleles; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Humans; Male; Neiss

2020
Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016.
    BMC infectious diseases, 2021, Mar-18, Volume: 21, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria

2021
In brief: New recommendations for gonococcal infection.
    The Medical letter on drugs and therapeutics, 2021, 05-03, Volume: 63, Issue:1623

    Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; Microbial Sensitivity Tests; Sexual Partners

2021
Tracking Antimicrobial Resistance in Neisseria gonorrhoeae from the Molecular Level Using Endocervical Swabs.
    Laboratory medicine, 2022, Jan-06, Volume: 53, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Female; Gono

2022
WGS to predict antibiotic MICs for Neisseria gonorrhoeae.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Anti-Bacterial Agents; Azithromycin; Canada; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; En

2017
A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Dr

2017
Antimicrobial susceptibility in
    Sexually transmitted infections, 2018, Volume: 94, Issue:1

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Ciprofloxacin; Disk D

2018
Emergence and Spread of Neisseria gonorrhoeae Isolates With Decreased Susceptibility to Extended-Spectrum Cephalosporins in Argentina, 2009 to 2013.
    Sexually transmitted diseases, 2017, Volume: 44, Issue:6

    Topics: Anti-Bacterial Agents; Argentina; Cefixime; Ceftriaxone; Cephalosporin Resistance; Gonorrhea; Humans

2017
Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.
    BMC infectious diseases, 2017, 09-11, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin R

2017
High levels of susceptibility to new and older antibiotics in Neisseria gonorrhoeae isolates from Saskatchewan (2003-15): time to consider point-of-care or molecular testing for precision treatment?
    The Journal of antimicrobial chemotherapy, 2018, Jan-01, Volume: 73, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Child; Child, P

2018
Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study.
    PLoS medicine, 2017, Volume: 14, Issue:10

    Topics: Anti-Bacterial Agents; Asymptomatic Infections; Bisexuality; Cefixime; Cephalosporin Resistance; Cos

2017
Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed.
    PLoS medicine, 2017, Volume: 14, Issue:10

    Topics: Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivit

2017
Accuracy and reproducibility of the Etest to detect drug-resistant Neisseria gonorrhoeae to contemporary treatment.
    Journal of medical microbiology, 2018, Volume: 67, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; H

2018
Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance.
    BMC infectious diseases, 2018, 01-17, Volume: 18, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporin Resistance; Cervix

2018
Antimicrobial resistance and molecular characterisation of Neisseria gonorrhoeae isolates in Fukuoka, Japan, 1996-2016.
    Journal of global antimicrobial resistance, 2019, Volume: 17

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorr

2019
Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016.
    BMC infectious diseases, 2018, Dec-03, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxo

2018
Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility.
    Sexual health, 2019, Volume: 16, Issue:5

    Topics: Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivit

2019
Recognition of the β-lactam carboxylate triggers acylation of
    The Journal of biological chemistry, 2019, 09-20, Volume: 294, Issue:38

    Topics: Acylation; Alleles; Binding Sites; Catalytic Domain; Cefixime; Ceftriaxone; Cephalosporin Resistance

2019
Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; Cefixime; Cefpodoxime; Ceftizoxime; Cepha

2013
Cephalosporin resistance in Neisseria gonorrhoeae infections.
    JAMA, 2013, May-15, Volume: 309, Issue:19

    Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae

2013
Cephalosporin resistance in Neisseria gonorrhoeae infections--reply.
    JAMA, 2013, May-15, Volume: 309, Issue:19

    Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae

2013
Cephalosporin resistance in Neisseria gonorrhoeae infections--reply.
    JAMA, 2013, May-15, Volume: 309, Issue:19

    Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae

2013
Cephalosporin resistance in gonorrhoea.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:9

    Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse

2013
Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacteria

2013
Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; beta-Lactam Resistance; Cefixime; Ceftriax

2013
Neisseria gonorrhoeae multiantigen sequence typing is beneficial in further characterizing gonococcal populations in Alberta, Canada.
    Sexually transmitted diseases, 2013, Volume: 40, Issue:9

    Topics: Alberta; Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Bacterial Typing Techniques; Cefi

2013
Gonococcal susceptibility to cephalosporins--Hawaii, 2003 to 2011.
    Sexually transmitted diseases, 2013, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Drug Resi

2013
Does the '2012 IUSTI ECCG report on the diagnosis and management of Neisseria gonorrhoeae infections in Europe' depict the situation in Europe?
    International journal of STD & AIDS, 2013, Volume: 24, Issue:6

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Disease Management; Europe; Gonorrhea; Health Services

2013
Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada.
    Sexually transmitted diseases, 2013, Volume: 40, Issue:11

    Topics: Adult; Alberta; Anti-Bacterial Agents; Azithromycin; Cefixime; Drug Therapy, Combination; Female; Go

2013
Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012.
    BMC infectious diseases, 2013, Dec-26, Volume: 13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxo

2013
Phylogenomics for drug-resistant Neisseria gonorrhoeae.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Male; Neisseria gonorr

2014
Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Genome, Bacterial; Genotype; Gonorrhea; H

2014
Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6

    Topics: Anti-Bacterial Agents; beta-Lactams; Cefixime; Ertapenem; Gonorrhea; Humans; Inhibitory Concentratio

2014
Molecular epidemiology of Neisseria gonorrhoeae isolates from Saskatchewan, Canada: utility of NG-MAST in predicting antimicrobial susceptibility regionally.
    Sexually transmitted infections, 2014, Volume: 90, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Cefixime;

2014
Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a 'susceptible' Neisseria gonorrhoeae population.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6

    Topics: Amino Acid Substitution; Bacterial Proteins; Canada; Cefixime; Ceftriaxone; Drug Resistance, Bacteri

2014
Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins.
    BMC infectious diseases, 2014, Feb-25, Volume: 14

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Child

2014
Decreased susceptibility to cephalosporins among gonococci?
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse

2014
Decreased susceptibility to cephalosporins among gonococci?
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse

2014
Decreased susceptibility to cephalosporins among gonococci? Authors' reply.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse

2014
Decreased susceptibility to cephalosporins among gonococci?
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:3

    Topics: Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Humans; Male; Neisse

2014
Mitigating the emergence and spread of multidrug- and extensively drug-resistant gonorrhea: is there sufficient support in resource-poor settings in Africa?
    Sexually transmitted diseases, 2014, Volume: 41, Issue:4

    Topics: Africa; Anti-Bacterial Agents; Cefixime; Drug Resistance, Multiple, Bacterial; Female; Gonorrhea; Gu

2014
Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:8

    Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Bacterial Typing Techniques; Ce

2014
Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2014, Nov-13, Volume: 19, Issue:45

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Europe; E

2014
Changes in the six most common sequence types of Neisseria gonorrhoeae, including ST4378, identified by surveillance of antimicrobial resistance in northern Taiwan from 2006 to 2013.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2016, Volume: 49, Issue:5

    Topics: Anti-Bacterial Agents; Antigens, Bacterial; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Ciprofl

2016
Can previous first-line therapies for Neisseria gonorrhoeae be targeted to specific patient subgroups to treat gonorrhea?
    Sexually transmitted diseases, 2015, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; Engla

2015
Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe.
    Sexually transmitted diseases, 2014, Volume: 41, Issue:12

    Topics: Adult; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Resistance, Microbial; Europ

2014
Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.
    BMC infectious diseases, 2015, Aug-11, Volume: 15

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Europe; Female; Gonorrhea; Humans;

2015
Gonococcal Conjunctivitis Despite Successful Treatment of Male Urethritis Syndrome.
    Sexually transmitted diseases, 2016, Volume: 43, Issue:2

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Conjunctivitis; Gonorrhea; Humans; Male; Neisseria go

2016
Neisseria gonorrhoeae Resistant to Ceftriaxone and Cefixime, Argentina.
    Emerging infectious diseases, 2016, Volume: 22, Issue:6

    Topics: Alleles; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; Cefixime; Ceftri

2016
Genetic Resistance Determinants for Cefixime and Molecular Analysis of Gonococci Isolated in Italy.
    Microbial drug resistance (Larchmont, N.Y.), 2017, Volume: 23, Issue:2

    Topics: Alleles; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone;

2017
Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:11

    Topics: Adult; Alleles; Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Cephalosporins; Female; G

2016
Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary.
    Annals of clinical microbiology and antimicrobials, 2016, Sep-20, Volume: 15, Issue:1

    Topics: Adult; Alleles; Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Cefixime; Ceftriax

2016
Reduced susceptibility to cefixime but not ceftriaxone: an uncertain perspective for the treatment of gonorrhoea in Brazil.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Brazil; Cefixime; Ceftriaxone; Female; Gonorrhea; High-Throughput Nucl

2017
Antimicrobial Susceptibility Evaluation and Multiple-Locus Variable Number Tandem Repeat Analysis of Neisseria gonorrhoeae Isolates in China in 2012.
    Sexually transmitted diseases, 2017, Volume: 44, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cervix Uteri; Chi-Square Distribution; China; C

2017
Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.
    Sexually transmitted infections, 2009, Volume: 85, Issue:4

    Topics: Anti-Bacterial Agents; Asia, Southeastern; Australia; Cefixime; Cefotaxime; Ceftriaxone; Cephalospor

2009
Antimicrobial resistance in gonorrhea: the influence of epidemiologic and laboratory surveillance data on treatment guidelines: Alberta, Canada 2001-2007.
    Sexually transmitted diseases, 2009, Volume: 36, Issue:10

    Topics: Adult; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gonorrhea; Humans; Male; Neisser

2009
Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Topics: Anti-Bacterial Agents; Base Sequence; Cefixime; Cephalosporin Resistance; Chromosomes, Bacterial; Go

2010
Diagnosis and treatment of urethritis in men.
    American family physician, 2010, Apr-01, Volume: 81, Issue:7

    Topics: Adolescent; Adult; Azithromycin; Black or African American; Cefixime; Ceftriaxone; Chlamydia Infecti

2010
Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden.
    Sexually transmitted infections, 2010, Volume: 86, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Cefixime; Ceftriaxone; Communic

2010
Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:12

    Topics: Amino Acid Sequence; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporin Resistance; Fimbria

2010
Quick recertification series. Gonorrhea.
    JAAPA : official journal of the American Academy of Physician Assistants, 2010, Volume: 23, Issue:11

    Topics: Administration, Oral; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Female; Gonorrhea; Humans; Injec

2010
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:2

    Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; Cephalosporin

2011
Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2010, Nov-25, Volume: 15, Issue:47

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Gonorrhea; Humans;

2010
Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2011, Apr-07, Volume: 16, Issue:14

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Drug Resistance, Multiple, Bacterial; England; Female

2011
[Gonorrhea--time for new guidelines].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Apr-08, Volume: 131, Issue:7

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Ciprofloxacin; Drug Resistance, Bacterial; F

2011
Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2011, Volume: 119, Issue:6

    Topics: Alleles; Anti-Bacterial Agents; Cefixime; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Dos

2011
Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Drug Resistance, Bacterial; Gonorrhea; Humans; Male; Microbi

2011
Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.
    MMWR. Morbidity and mortality weekly report, 2011, Jul-08, Volume: 60, Issue:26

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Female; Go

2011
Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefixime; Ciprofloxacin; Drug Resistance, Multiple,

2011
Characterization of profile of multidrug-resistant Neisseria gonorrhoeae using old and new definitions in India over a decade: 2000-2009.
    Sexually transmitted diseases, 2011, Volume: 38, Issue:11

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Human

2011
First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2011, Oct-27, Volume: 16, Issue:43

    Topics: Anti-Bacterial Agents; Austria; Cefixime; Cephalosporin Resistance; Gonorrhea; Humans; Male; Neisser

2011
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3

    Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Biomarkers; Cefixime; Ceftriaxone; Cephalospori

2012
Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test.
    Acta dermato-venereologica, 2012, Volume: 92, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefixime; Cervix Uteri; Ciprofloxacin; Drug Resistan

2012
Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010.
    Sexually transmitted diseases, 2012, Volume: 39, Issue:4

    Topics: Adolescent; Adult; Canada; Cefixime; Ceftriaxone; Drug Resistance, Microbial; Female; Gonorrhea; Hum

2012
Management of pharyngeal gonorrhea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonorrhoeae.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Cephalosporin Resistance; Gonorrhea; Humans; Male; Nei

2012
Antimicrobial susceptibility and penicillin-binding protein 1 and 2 mutations in Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Cephalosporin Resistance; Cephalosporins; Gonorrhea; Humans; Japan;

2013
Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.
    MMWR. Morbidity and mortality weekly report, 2012, Aug-10, Volume: 61, Issue:31

    Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Centers for Diseas

2012
Tackling multidrug-resistant gonorrhea: how should we prepare for the untreatable?
    Expert review of anti-infective therapy, 2012, Volume: 10, Issue:8

    Topics: Anti-Bacterial Agents; Cefixime; Ceftriaxone; Drug Resistance, Multiple, Bacterial; Gonorrhea; Human

2012
Combination therapy for gonorrhoea: in vitro synergy testing.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:3

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Drug Synergism; Gentamicins; Gonorrhea;

2013
Update on Emerging Infections: news from the Centers for Disease Control and Prevention. Update to the CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections .
    Annals of emergency medicine, 2013, Volume: 61, Issue:1

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Ceftriaxone; Doxycycline; Female; Gonorrhea; Humans;

2013
Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.
    JAMA, 2013, Jan-09, Volume: 309, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Cefixime; Cohort Studies; Drug Resistance, Microbial; Female; Gonorrhe

2013
Cephalosporin-resistant gonorrhea in North America.
    JAMA, 2013, Jan-09, Volume: 309, Issue:2

    Topics: Anti-Bacterial Agents; Cefixime; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae

2013
Discontinuation of cefixime tablets--United States.
    MMWR. Morbidity and mortality weekly report, 2002, Nov-22, Volume: 51, Issue:46

    Topics: Anti-Bacterial Agents; Cefixime; Drug and Narcotic Control; Drug Resistance, Bacterial; Gonorrhea; N

2002
Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2003, Volume: 9, Issue:1

    Topics: Anti-Bacterial Agents; Cefixime; Drug Administration Schedule; Gonorrhea; Humans; Male; Microbial Se

2003
Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6

    Topics: Adult; Anti-Infective Agents; Cefixime; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gonorr

2003
Increasing cases of drug-resistant gonorrhea prompt new CDC treatment recommendations for gay and bisexual men.
    Report on medical guidelines & outcomes research, 2004, May-14, Volume: 15, Issue:10

    Topics: Cefixime; Ceftizoxime; Ceftriaxone; Centers for Disease Control and Prevention, U.S.; Contraindicati

2004
Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:1

    Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Cefixime; Drug Resistance, Bact

2005
Expedited treatment for partners of patients with gonorrhea and/or chlamydial infection: impact on rates of persistence or recurrence.
    Postgraduate medicine, 2005, Volume: 117, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Drug Therapy, Combinatio

2005
Gonorrhea: update.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2006, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Ceftriaxone; Child; Gonorrhea; Humans; Incidence

2006
School-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae among Philadelphia public high school students.
    Sexually transmitted diseases, 2006, Volume: 33, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Cefixime; Child; Chlam

2006
Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11

    Topics: Amino Acid Sequence; Amino Acid Substitution; Bacterial Proteins; Cefixime; Cephalosporins; Cloning,

2006
The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.
    International journal of STD & AIDS, 2007, Volume: 18, Issue:4

    Topics: Administration, Oral; Anti-Bacterial Agents; Cefixime; Chlamydia Infections; Chlamydia trachomatis;

2007
Pharyngeal gonorrhoea - is dual therapy the way forward?
    International journal of STD & AIDS, 2007, Volume: 18, Issue:9

    Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Chlamydia Infections; Doxycycline; Drug Therapy, Comb

2007
Threat to cefixime treatment for gonorrhea.
    Emerging infectious diseases, 2007, Volume: 13, Issue:8

    Topics: Adult; Base Sequence; Cefixime; Ceftriaxone; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulse

2007
Availability of cefixime 400 mg tablets--United States, April 2008.
    MMWR. Morbidity and mortality weekly report, 2008, Apr-25, Volume: 57, Issue:16

    Topics: Anti-Bacterial Agents; Cefixime; Gonorrhea; Humans; United States

2008
Acute septic arthritis: remember gonorrhea.
    Rheumatology international, 2008, Volume: 29, Issue:1

    Topics: Acute Disease; Anti-Bacterial Agents; Arthritis, Infectious; Cefixime; Ceftriaxone; Gonorrhea; Human

2008
Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis.
    Annals of emergency medicine, 1996, Volume: 27, Issue:3

    Topics: Administration, Oral; Adolescent; Anti-Infective Agents; Cefixime; Cefotaxime; Ceftriaxone; Cephalos

1996
Cost-effectiveness of management strategies for acute urethritis in the developing world.
    Tropical medicine & international health : TM & IH, 2000, Volume: 5, Issue:9

    Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Cost-Benefit Analysis; Decisi

2000
Sexually transmitted diseases in the 1990s.
    The New England journal of medicine, 1991, Nov-07, Volume: 325, Issue:19

    Topics: Cefixime; Cefotaxime; Ceftriaxone; Gonorrhea; HIV Infections; Humans; Sexually Transmitted Diseases

1991
[Cefixime therapy in patients with proven gonorrhea].
    Infection, 1990, Volume: 18 Suppl 3

    Topics: Acute Disease; Adult; Anti-Infective Agents; Cefixime; Cefotaxime; Drug Tolerance; Gonorrhea; Humans

1990
Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989, Volume: 8, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Cefixime; Cefotaxime; Gonorrhea; Humans; Male; Neisseria go

1989